- • Up to 20% off your first purchase
- • Bulk quantities available
- • Citation Reward application
Sample Application
- Animal health test
- In-vitro diagnostics
- Food & Feed Safety
- Environmental Safety
- New drug discovery
Supports
- Talk to our Expert:
[email protected] -
Talk to our sales:
[email protected]
Protocol Library Download
 |
 |
Anti-CO7/ C7 monoclonal antibody
Anti-CO7/ C7 antibody for FACS & in-vivo assay
Go to C7/C7 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)
MSDSProduct information
| Catalog No. | Product Name | Species Reactivity |
|---|---|---|
| GM-Tg-hg-MP2422-Ab-1/ GM-Tg-hg-MP2422-Ab-2 | Anti-Human C7 monoclonal antibody | Human |
| GM-Tg-rg-MP2422-Ab-1/ GM-Tg-rg-MP2422-Ab-2 | Anti-Rat C7 monoclonal antibody | Rat |
| GM-Tg-mg-MP2422-Ab-1/ GM-Tg-mg-MP2422-Ab-2 | Anti-Mouse C7 monoclonal antibody | Mouse |
| GM-Tg-cynog-MP2422-Ab-1/ GM-Tg-cynog-MP2422-Ab-2 | Anti-Cynomolgus/ Rhesus macaque C7 monoclonal antibody | Cynomolgus/ Rhesus macaque |
| GM-Tg-felg-MP2422-Ab-1/ GM-Tg-felg-MP2422-Ab-2 | Anti-Feline C7 monoclonal antibody | Feline |
| GM-Tg-cang-MP2422-Ab-1/ GM-Tg-cang-MP2422-Ab-2 | Anti-Canine C7 monoclonal antibody | Canine |
| GM-Tg-bovg-MP2422-Ab-1/ GM-Tg-bovg-MP2422-Ab-2 | Anti-Bovine C7 monoclonal antibody | Bovine |
| GM-Tg-equg-MP2422-Ab-1/ GM-Tg-equg-MP2422-Ab-2 | Anti-Equine C7 monoclonal antibody | Equine |
Size： 1mg | 10mg | 100mg
Product Description
| Catalog No. | GM-Tg-hg-MP2422-Ab-1/ GM-Tg-hg-MP2422-Ab-2; GM-Tg-rg-MP2422-Ab-1/ GM-Tg-rg-MP2422-Ab-2; GM-Tg-mg-MP2422-Ab-1/ GM-Tg-mg-MP2422-Ab-2; GM-Tg-cynog-MP2422-Ab-1/ GM-Tg-cynog-MP2422-Ab-2; GM-Tg-felg-MP2422-Ab-1/ GM-Tg-felg-MP2422-Ab-2; GM-Tg-cang-MP2422-Ab-1/ GM-Tg-cang-MP2422-Ab-2; GM-Tg-bovg-MP2422-Ab-1/ GM-Tg-bovg-MP2422-Ab-2; GM-Tg-equg-MP2422-Ab-1/ GM-Tg-equg-MP2422-Ab-2 |
| Products Name | Anti-C7 monoclonal antibody |
| Format | mab |
| Target Name | C7 |
| Protein Sub-location | Transmembrane Protein |
| Category of antibody | FACS/Biofunctional Antibody |
| Derivation (species) | Mouse |
| CH1+2+3 Isotype (Receptor identification) | IgG |
| Type of Light Chain (VD-LC) | N/A |
| Expression platform | Mammalian Expression |
| Bioactivity validation | Binding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD). |
| Tag | Fc |
| Products description | Pre-made anti-C7 benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) |
| Purity | Purity: ≥95% (SDS-PAGE) |
| Application | Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research. |
| Formulation & Reconstitution | Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O. |
| Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
Data / case study
Click to get more Data / Case study about the product.
Associated products
| Category | Cat No. | Products Name |
| Target Antigen | Products Developing | Multi-species CO7/ C7 VLP (virus-like particle) (Products Developing) |
| ORF Viral Vector | vGMLP002049 | human C7 Lentivirus particle |
| ORF Viral Vector | pGMLP002049 | human C7 Lentivirus plasmid |
Target information
| Target ID | GM-MP2422 |
| Target Name | C7 |
| Gene ID | 730,109828,117517,696926,489221,101094482,507339,100066126 |
| Gene Symbol and Synonyms | A530026G17,C7,Gm1238 |
| Uniprot Accession | P10643,Q29RQ1 |
| Uniprot Entry Name | CO7_HUMAN,CO7_BOVIN |
| Protein Sub-location | Transmembrane Protein |
| Category | |
| Disease | Prostate Cancer, kidney cancers, Diabetic Nephropathy |
| Gene Ensembl | ENSG00000112936 |
| Target Classification | N/A |
The target: C7, gene name: C7, also named as . This gene encodes a serum glycoprotein that forms a membrane attack complex together with complement components C5b, C6, C8, and C9 as part of the terminal complement pathway of the innate immune system. The protein encoded by this gene contains a cholesterol-dependent cytolysin/membrane attack complex/perforin-like (CDC/MACPF) domain and belongs to a large family of structurally related molecules that form pores involved in host immunity and bacterial pathogenesis. This protein initiates membrane attack complex formation by binding the C5b-C6 subcomplex and inserts into the phospholipid bilayer, serving as a membrane anchor. Mutations in this gene are associated with a rare disorder called C7 deficiency. [provided by RefSeq, Nov 2016].
About Gmab
GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.
Facebook
LinkedIn
Twitter
